BASKING RIDGE, N.J., April 9 /PRNewswire/ -- Regado Biosciences, Inc., a privately held company leading the development of antithrombotic aptamers with active control agents, announced that Steven Zelenkofske, DO, FACC, Senior Vice President, Chief Medical Officer, presented an abstract at the Arteriosclerosis, Thrombosis and Vascular Biology Scientific Sessions on April 9, 2010 at 5pm (PST) in San Francisco, CA. The poster, entitled "Subcutaneous RB006, a Direct FIXa Inhibitor Provides Prolonged Anticoagulation with Rapid Reversal; the First Clinical Experience with the REG2 System" is the initial presentation of top-line data from Regado's REG2-SC101 phase 1 study of the REG2 anticoagulation system. The REG2 system is Regado's second product candidate in development, which consists of a subcutaneously administered formulation of the specific Factor IXa inhibitor, RB006, paired with an IV bolus formulation of its complementary active control agent, RB007.
ABOUT REGADO BIOSCIENCES
Regado Biosciences is pioneering a new therapeutic technology with the creation and development of two-component drug systems. Each system comprises a nuclease-stabilized RNA aptamer that can be controlled directly by its specific and complementary oligonucleotide active control agent. This technology is being applied to injectable antithrombotics (including anticoagulants and antiplatelet agents) in the acute and sub-acute care setting, a multi-billion dollar market in need of therapeutics with improved safety profiles and a greater degree of therapeutic control. Regado's technology is designed to give physicians the ability to actively and directly control each system's therapeutic effect providing a safe and unique approach to personalized medicine.
ABOUT APTAMERS
RB006 is a member of a class of compounds called aptamers. Aptamers are single stranded oligonucleotides that adopt a specific conformation enabling direct, specific inhibition of the targeted protein. A key unique feature of aptamers derives from the fact that they are formed from nucleic acids. As such, their pharmacologic activity can be controlled by a matched, complementary oligonucleotide active control agent (the Watson-Crick base pair complement of a fraction of the agent to be controlled), which can bind to the aptamer, removing it from its target and reversing it biologic effects.
Regado Biosciences, Inc.